



Forteo® (teriparatide) – Updated drug label

- On November 16, 2020, the [FDA approved](#) several updates to Eli Lilly's [Forteo \(teriparatide\)](#) drug label, including:
 - The removal of the boxed warning regarding osteosarcoma
 - Modification of the dosing and administration section to allow for longer duration of treatment in patients who remain at or return to having a high risk for fracture
 - Addition of the risk of cutaneous calcification including calciphylaxis to the existing warning regarding hypercalcemia and hypercalcemic disorders.
- Forteo is approved for:
 - Treatment of postmenopausal women with osteoporosis at high risk for fracture
 - Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture
 - Treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture.
- The recommended dose of Forteo is 20 mcg subcutaneously once a day.
- The new recommended treatment duration section of the drug label states that the use of Forteo for more than 2 years during a patient's lifetime should only be considered if a patient remains at or has returned to having a high risk for fracture.
 - Previously, the treatment duration section stated that the safety and efficacy of Forteo had not been evaluated beyond 2 years of treatment. Consequently, use of the drug for more than 2 years during a patient's lifetime was not recommended.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.